Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7919899 | 0.88 | NOTUM (0.47) | NOTUMEGLN2HCRTR1HCRTR2CSNK2A1 | |
| SCHEMBL302595 | 0.87 | NOTUM (0.46) | NOTUMEGLN2HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL4457296 | 0.83 | NOTUM (0.49) | NOTUMHCRTR1HCRTR2 | |
| SCHEMBL28457554 | 0.83 | MYC (0.50) | NOTUMHCRTR1HCRTR2 | |
| SCHEMBL19894027 | 0.82 | MYC (0.51) | NOTUM | |
| SCHEMBL1586107 | 0.81 | HCRTR1 (0.58) | NOTUMHCRTR1HCRTR2 | |
| SCHEMBL30767902 | 0.80 | NOTUM (0.46) | NOTUM | |
| SCHEMBL27774578 | 0.78 | NOTUM (0.40) | NOTUMHCRTR1HCRTR2 | |
| SCHEMBL19481007 | 0.78 | — | — | |
| SCHEMBL30005880 | 0.78 | HCRTR1 (0.50) | NOTUMHCRTR1HCRTR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787432-B2 | N-[(pyridyloxy)propanyl]benzamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-09-29 | — | — | US | disclosed |
| US-10787432-B2 | N-[(pyridyloxy)propanyl]benzamides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-09-29 | — | — | US | disclosed |
| EP-3442958-B1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| EP-3442958-B1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2020-05-06 | — | — | EP | disclosed |
| US-20190112291-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190112291-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| WO-2017178340-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-19 | — | — | WO | disclosed |
| US-9695183-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9637496-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-29 | — | — | US | disclosed |
| US-9475819-B2 | Substituted 7-azabicycles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-25 | — | — | US | disclosed |
| US-20160046640-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| EP-2970313-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-19 | — | — | US | disclosed |
| US-9062078-B2 | Substituted 7-azabicyles and their use as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| WO-2014159591-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-09-18 | — | — | US | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046640-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, HTR7 | NOTUM 3690/4885EGLN2 399/4885HCRTR1 2/4885 |
| US-20150328224-A1 | SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | NOTUM 3333/4885EGLN2 570/4885HCRTR1 2/4885 |
| US-20160376280-A1 | Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators | HCRTR2, HCRTR1, NPY5R | NOTUM 3233/4885EGLN2 533/4885HCRTR1 2/4885 |
| US-10787432-B2 | N-[(pyridyloxy)propanyl]benzamides | HCRTR1, HCRTR2, CNR1 | NOTUM 2182/4885EGLN2 287/4885HCRTR1 1/4885 |
| US-20190112291-A1 | NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES | HCRTR1, HCRTR2, CNR1 | NOTUM 2295/4885EGLN2 317/4885HCRTR1 1/4885 |
| US-20140275065-A1 | SUBSTITUTED 7-AZABICYLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, NPY5R | NOTUM 2993/4885EGLN2 603/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.